ストックスクリーナーアプリを入手
3.01
5.05%
-0.16
アフターアワーズ：
3.02
0.01
+0.33%
Perspective Therapeutics Inc (CATX) 最新ニュース
CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus
Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times
Perspective Therapeutics taps Merck KGaA oncology chief in planned science shift - Stock Titan
Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr
Perspective Therapeutics (CATX) Proxy filing Summary - Quartr
Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr
Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan
Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan
CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView
Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
CATX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Investor ConfidenceEarnings Revision Downgrade - dars.gov.et
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Enliven Therapeutics Surges on Promising Leukemia Drug Trial ResultsEarnings Outlook Update - newsline.com
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort - Moomoo
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Clinical ProgressForward Guidance Trends - newsline.com
Perspective Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Yahoo Finance
Perspective Therapeutics (CATX) Initiates Meningioma Patient Stu - GuruFocus
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
Targeted alpha therapy trial doses first patient for common brain tumor - Stock Titan
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy - TradingView
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update - Stock Titan
H.C. Wainwright Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $13 - Moomoo
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - thelegaladvocate.com
Perspective Therapeutics (CATX) Slides 2.72% as Stock Tests Key Support LevelsBollinger Squeeze - newsline.com
Edgewise Therapeutics Inc. (EWTW) Q1 2026 Earnings: Narrower Losses Bolster Investor SentimentRevenue Estimate Trend - thelegaladvocate.com
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneLarge Cap Trends - thelegaladvocate.com
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting - Yahoo Finance
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Surprise History - thelegaladvocate.com
Fluidra Appoints Juan Graham as Chief Financial Officer - hrtoday.in
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - thelegaladvocate.com
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance - Minichart
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026 - Yahoo Finance
2.36%
大文字化:
|
ボリューム (24 時間):